The 6774 option shares that were exercised and sold on 10/15/2015 were the last available at that time!
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date
(MM/DD/YY) 7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 11. Nature of Indirect Beneficial Ownership
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $ 0.875 10/15/2015 M( 1 ) 10,000 06/25/2008 06/25/2018 Common Stock 6,774 $ 0 0 D
Reporting Owners Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
C/O CYTOSORBENTS CORPORATION
7 DEER PARK DRIVE, SUITE K
MONMOUTH JUNCTION, NJ08852 X
Signatures /s/ Ronald E. Berger, attorney-in-fact For Al Kraus 10/19/2015
** Signature of Reporting Person Date
No, your rewording is also not factually correct. As can be seen from all the Form 4s, all the options that Al Kraus was selling through mid-October 2015 were from the same grant that first became exercisable on 06/25/2008 and would have expired on 06/25/2018.
As can be seen from various other filings (10Ks, S-1/As, DEF 14As), the vast majority of his other options were granted well *BEFORE* mid-October 2015, for his services as chairman and board director, etc.
Sentiment: Strong Buy
No one is buying your story - or mine right now either. I laid out a scenario in which an investor today would reap an annualized return of 50%+over next four years -- Who wouldn't jump at that chance? - Apparently very, very few retail or institutional investors as the abysmally low volume illustrates.
And I don't believe it's from lack of exposure. As DC likes to trumpet they're now approved in 32 countries, it's in 100's of hospitals, increasing numbers of medical professionals are using & touting the device and DC has attended countless investment conferences over the seven years I've held the stock- More people than ever before are aware of the opportunity, yet it sits at a paltry $4.00 - Why? - Big money is leery of true ( not what you & DC sing) future revenue, the competence of management to bring the company to the next level in a timely manner and a host of other threats that would invite a buy-out of the proportions you envision- Time will tell
Poor Al...he is taking a lot of heat for the 15 cent cytosorbet. Was Al responsible for building the scientific data base? Was Al in charge of clinical development here in the US? What about the German sepsis trial, was Al responsible for final data gonculatons? Hard to believe that a company on the cusp of saving the world from so many evil diseases can have it's share price stunted by one senior individual selling a little stock here and there so he can treat his family to the occasional ice cream cone. Harder to believe that we as market savy Americans are willing to buy the story that Al's selling is the reason we are below the price we were at after the stock consolidated. Maybe there is more to the story than Al's selling slowing our valuation...maybe you folks better wonder just what is going on here....the name Fresenius hasn't been used yet today...why not headline that 6 or 7 times, it could cause us to pop a dime on Tuesday.
Pearsby, you might be right from your perspective. You seem to be on the same side as Kraus. See, Napoleon was also successful at the beginning of his career. What try to explain is the fact that Kraus can't reliquish "his" company. Elderly persons, as a CEO or as member of the board - tend to keep what they did for the company, but are not in the position to keep up with fresh and promising ideas. This attitude blocks a company for a certain time - but not for ever. Guess that Dr. Chan and a majority of the CTSO shareholders are very much looking forward for the day of the Kraus' resignation.
He exercised and sold the last of his options on Oct.15, 2015. Still held some common. I should have worded it this way! So he was granted more options after Oct 15, 2015.
Sorin Goup and MAQUET Sponsors at the June 1st where Cytosorbents will have a booth.
You just confirmed why you're such a ignorant idiot Greg.
I will gladly stick around the CTSO board long after I'm done making money on one of the most predictable company i've ever witnessed just to "F" with you Greg.
Ok, you are gay, but that is ok now. And, you have stolen multiple ID's including mine to make sure someone agrees with your misleading, maniputative posts.
Sentiment: Strong Buy
You have never read a 10-Q. Had you, you would have certainly known where i was quoting the analyst in CTSO 10-Q, you taking about standard verbiage is a laugh.
Just stick to calling people gay and connecting posters to aliases it's what you're good at DS
So you are quoting the Standard Bollerplate verbagr of every developmental company and trying to scare people?
Sentiment: Strong Buy
Yes, in theory, one board member should not hold that much sway. But Kraus has been Chairman of the Board since 2009, and served as President and CEO from 2003 to 2008, before Chan took over.
Thus, it's not too difficult to believe Kraus have lots of strong opinions that may unduly sway the other members of the board, especially the newer, independent members. The CTSO board only has 5 seats, so Kraus only has to get 2 of the 3 other directors if his view is contrary to Chan's.
If there is any internal Board strife, I don't think it's realistic for them to officially confirm it to any external investor.
This is a predominantly retail-held stock, so if you feel like CTSO should make Board changes, vote your shares accordingly. I certainly have.
Sentiment: Strong Buy
If you invest in a company that awards stock options to management and board members, you should probably expect those options to be exercised at some point especially if expiration is near. Kraus has not "single handily" stopped anybody, and you have no knowledge of whether he is low class or not.
If Kraus is holding us back, somebody needs to talk to management and find out what is going on. I am not sure one board member has enough power to stop the initiatives of management.
Looks like contract for the ARDS Network ended on June 30, 2014. Four of our REFRESH I clinical centers were members ARDSNet I (Baylor, Baystate, U of Maryland, and U of Pittsburgh), and three were members of ARDSNet II (Baylor, Baystate, and U of Maryland).
The NHLBI-funded successive network is called Prevention & Early Treatment of Acute Lung Injury (PETAL). They seem to be just getting started, but it looks like U of Pittsburgh is the only REFRESH I participating center that is a member of PETAL so far.
Here are the goals of PETAL:
(1) Develop new innovative approaches to prevent and improve the outcomes of patients who are at risk for ARDS including patients in shock or respiratory failure from sepsis.
(2) Build on findings from the ARDS Network to develop earlier treatments for patients with ARDS
(3) Develop collaborative working relationships between pulmonary/critical care and emergency department disciplines
(4) Establish a collection of biospecimens to aid both network investigators and the greater research community in studying the disease process in critically ill patients and finding better ways to treat them.
(5) Seek input from the international emergency and critical care community
I especially like (1), (3), and (5).
A reminder about ARDS (from the ARDS Network site): "There is no proven drug treatment for ARDS per se. Current management of ARDS begins with treatment and stabilization of the underlying disease that caused ARDS, such as early and effective antibiotics for pneumonia or sepsis. The injured lung should be managed gently with small breaths and low pressures from the ventilator (so called low tidal volume and pressure ventialtion). In addition, conservative use of intravenous fluids combined with removal of excess fluids with diruetics lessens the need for mechanical ventilation. With these supportive measures, the lung may heal quickly and the patient can return to normal breathing in days; in severe cases ARDS may enter a prolonged phase of healing that may require weeks to resolve. In even more severe cases, devastating lung injury cannot support life or other organs fail along with the lung (a condition known as multiple organ failure). Death may occur in up to 40 percent of cases in this severe form."
It would be nice for CTSO to get on PETAL's radar, as they can help CTSO with funding large, multi-center, randomized clinical trials.
Sentiment: Strong Buy
Nice comments....I don't know who this fellow is although Im sure is a credible, delightful and a honest man. Is he by chance also part of the failed or restructured sales group in Germany that caused us to come up way short on the analyst sales guidance. I know all regulars remember that we were supposed to do 15 millions in sales and ended up at 4 millions. Was this fellow the key salesguy that led to this drop in share price from 15 dollars to 4 dollars? I thought the name looked Germain, just a guess on my part.